Comparison of Anticoagulant Effects and Safety of Argatroban and Heparin in Healthy Subjects (original) (raw)
A Review of an Unorthodox Argatroban Infusion Rate for Anticoagulation in a Patient Case
Journal of Pharmacy and Pharmacology
Journal of Pharmacy and Pharmacology 5 (2017) 189-193, 2017
View PDFchevron_right
Weight-Based Argatroban Dosing Nomogram for Treatment of Heparin-Induced Thrombocytopenia
Alexander Ansara, R. Warhurst
Annals of Pharmacotherapy, 2009
View PDFchevron_right
Clinical Experience with Argatroban for Heparin-Induced Thrombocytopenia in a Large Teaching Hospital
Duane Bates
The Canadian Journal of Hospital Pharmacy, 2009
View PDFchevron_right
Argatroban in the management of heparin-induced thrombocytopenia
Vittorio Pengo
Vascular Health and Risk Management, 2010
View PDFchevron_right
Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients
Eliezer Katz
Clinical and Applied Thrombosis/Hemostasis, 2007
View PDFchevron_right
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing
Amanda Drenth
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2008
View PDFchevron_right
Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin - a model-based study
Gyorgy Frendl
Clinical pharmacology : advances and applications, 2015
View PDFchevron_right
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation
Job Harenberg
Clinical chemistry, 2002
View PDFchevron_right
Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis
Paul Barash, Viji Kurup
2010
View PDFchevron_right
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
Ramin Artang
Research and Practice in Thrombosis and Haemostasis, 2017
View PDFchevron_right
Introductory Chapter: Anticoagulant Therapy in Clinical Practice - Challenges and Wishes
Mina kelleni
Anticoagulation Drugs - the Current State of the Art, 2020
View PDFchevron_right
Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin-Induced Thrombocytopenia
Tyree Kiser
Pharmacotherapy, 2005
View PDFchevron_right
The International Normalized Ratio during Concurrent Warfarin and Argatroban Anticoagulation: Differential Contributions of Each Agent and Effects of the Choice
Jean-Claude Becker
2000
View PDFchevron_right
Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin-Induced Thrombocytopenia
Jean Nappi
Pharmacotherapy, 2006
View PDFchevron_right
A Synopsis of the Clinical Uses of Argatroban
Mubina Moledina
Journal of Thrombosis and Thrombolysis, 2001
View PDFchevron_right
Argatroban Dosage Requirements and Outcomes in Intensive Care versus Non–Intensive Care Patients
Joan Mattson
Pharmacotherapy, 2009
View PDFchevron_right
Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010
Jawed Fareed
Seminars in Thrombosis and Hemostasis, 2008
View PDFchevron_right
Urgent Need to Measure Effects of Direct Oral Anticoagulants: Table
Jeffrey Weitz
Circulation, 2016
View PDFchevron_right
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes—observations from the TARGET trial
Nasser Lakkis
The American Journal of Cardiology, 2003
View PDFchevron_right
Argatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1): A Randomized, Placebo-Controlled Safety Study
Marian Lamonte
Stroke, 2004
View PDFchevron_right
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Henri Spronk
Critical Care, 2014
View PDFchevron_right
Promise and challenges of anticoagulation with dabigatran
Ashish Verma
Clinical Kidney Journal, 2012
View PDFchevron_right
Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?
Maria Elaine Floriano
Interactive CardioVascular and Thoracic Surgery, 2010
View PDFchevron_right
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study
Oscar Dutra
Journal of the American College of Cardiology, 1999
View PDFchevron_right
Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
GUALTIERO PALARETI
Journal of Thrombosis and Haemostasis, 2013
View PDFchevron_right
C0416: Thrombin Generation Test in Patients Under New Oral Anticoagulants (Dabigatran and Rivaroxaban)
N. Cabrera, Fernando Ferrando
Thrombosis Research, 2014
View PDFchevron_right
Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
Vedran Velagić
Clinical Cardiology, 2021
View PDFchevron_right
Point-of-Care Coagulation Testing for Assessment of the Pharmacodynamic Anticoagulant Effect of Direct Oral Anticoagulant
Alexander Kasper
Therapeutic Drug Monitoring, 2014
View PDFchevron_right
Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention
Tien Nguyen
The American Journal of Cardiology, 2001
View PDFchevron_right
A Guide to Anticoagulant Therapy
BENJAMIN ALEXANDER
Circulation, 1961
View PDFchevron_right
Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?
Emmanuel Favaloro
Clinical Chemistry and Laboratory Medicine, 2000
View PDFchevron_right
Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemo
Gualtiero Palareti, Anna Falanga
Journal of Thrombosis and Haemostasis, 2013
View PDFchevron_right